Ovid Therapeutics (OVID) Set to Release Quarterly Earnings on Wednesday

Key Points

• Ovid Therapeutics is scheduled to report Q3 2026 results before the market opens Wednesday, November 11. Analysts forecast a loss of $0.08 per share and revenue of $0.03 million; the earnings call is scheduled for November 13.
• In its previous quarter, Ovid reported a loss of $0.08 per share, beating the consensus estimate of a $0.12 loss, and revenue of $0.73 million versus expectations of $0.02 million.
• Analysts’ consensus rating is Moderate Buy, with a $6.00 average price target. Ratings include 12 Buy or Strong Buy recommendations and one Sell.

Ovid Therapeutics (NASDAQ:OVID - Get Free Report) is expected to post its Q3 2026 results before the market opens on Wednesday, November 11th. Analysts expect Ovid Therapeutics to announce earnings of ($0.08) per share and revenue of $0.03 million for the quarter. Interested persons can check the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 13, 2026 at 9:30 AM ET.

Ovid Therapeutics (NASDAQ:OVID - Get Free Report) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.12) by $0.04. The company had revenue of $0.73 million for the quarter, compared to the consensus estimate of $0.02 million. On average, analysts expect Ovid Therapeutics to post ($0.37) EPS for the current fiscal year and ($0.38) EPS for the next fiscal year.

Ovid Therapeutics Trading Up 0.8%

OVID opened at $2.41 on Wednesday. The firm's 50-day simple moving average is $2.52 and its 200-day simple moving average is $2.36. The company has a quick ratio of 12.39, a current ratio of 12.39 and a debt-to-equity ratio of 0.05. Ovid Therapeutics has a twelve month low of $1.18 and a twelve month high of $3.11.

Analysts Set New Price Targets

Several analysts have weighed in on the stock. HC Wainwright upped their price objective on shares of Ovid Therapeutics from $4.00 to $5.00 and gave the stock a "buy" rating in a research note on Friday, September 11th. Roth Capital reiterated a "buy" rating and issued a $8.00 price objective on shares of Ovid Therapeutics in a research report on Thursday, September 3rd. Oppenheimer upped their target price on shares of Ovid Therapeutics from $7.00 to $9.00 and gave the stock an "outperform" rating in a research report on Monday, August 3rd. Wolfe Research assumed coverage on Ovid Therapeutics in a report on Thursday, October 15th. They issued an "outperform" rating and a $5.00 price target on the stock. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Ovid Therapeutics in a report on Thursday, October 15th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Ovid Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $6.00.

Ovid Therapeutics Company Profile

Ovid Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines for epilepsies and other disorders of the central nervous system. The company's research has concentrated on conditions with significant unmet medical needs, including rare epileptic and neurodevelopmental disorders.

Ovid's pipeline has included soticlestat, an investigational therapy developed in collaboration with Takeda Pharmaceutical Company for developmental and epileptic encephalopathies such as Dravet syndrome and Lennox-Gastaut syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.